JP Morgan Maintains Neutral on Pfizer, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott has maintained a Neutral rating on Pfizer (NYSE:PFE) and lowered the price target from $39 to $36.
October 06, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained a Neutral rating on Pfizer and lowered the price target from $39 to $36.
The lowering of the price target by JP Morgan could potentially lead to a negative sentiment among investors, which may put downward pressure on Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100